San Diego Anti-aging medicine and family practice located in Encinitas CA, Center for Age Management

Optimize Your Health
Center for Age Management

317 N. El Camino Real, Suite 206
Encinitas, CA 92024
USA View Map

Phone: 760-633-1315


Mon - Thur: 9am to 5pm
Lunch: 12pm to 1:30pm
Friday: 9am to 12pm
On Fridays, we will have limited staff. You may leave a message and it will be our pleasure to return your call. Any prescriptions, questions or concerns that you have, we will be happy to assist you Monday - Thursday.

Serving other neighboring cities: La Costa, Solana Beach, Rancho Santa Fe, Del Mar, San Marcos, Carlsbad, La Jolla, and San Diego County, CA.

A Randomized, Placebo-Controlled Trial

Howard B.A. Baum, MD; Beverly M.K. Biller, MD; Joel S. Finkelstein, MD;
Kristin Baker Cannistraro, BS, RN; Daniel S. Oppenheim, MD, PhD; David A. Schoenfeld, PhD; Theresa
Hoskins Michel, PT, MS; Harriet Wittink, PT, MS; and Anne Klibanski, MD
‘ Background: Patients with adultonset growth hormone deficiency have reduced bone density and increased fat mass. Growth hormone at high doses may decrease body fat in these patients, but the effects of growth hormone at more physiologic doses on bone density and body compo- sifion have not been convincingly shown.

Objective: To determine whether long-term growth hor- mone therapy at a dose adjusted to maintain normal insulin= like growth factor 1 (lGF~‘l) levels has clinical effects in patients with adult-onset growth hormone deficiency. Design: Randomized, placebo—c0ntrolled study. Setting: Tertiary referral center. Patients: 32 men with adult-onset growth hormone de- ficiency. Intervention: Growth hormone (initial daily dose, 10 /utg/kg of body weight) or placebo for 18 months. The growth hormone dose was reduced by 25% if lGF1 levels were elevated. Measurements: Body composition and bone mineral density of the lumbar spine, femoral neck, and proximal radius were measured by dual energy x-ray abs0rpliom— etry at 6-month inten/als. Markers of bone turnoverwere also measured during the first 12 months of the study.

Results: Growth hormone therapy increased bone min- eral density in the lumbar spine by a mean (1 SD) of 5.1% 1 4.1% and bone mineral density in the femoral neck by 2.4% 1 3.5%. In the growth hormone group, signif- icant increases were seen in the following markers of bone turnover: osteocalcin (4.4 1 3.6 mg/L to 7.2 1 4.6 mg/L) and urinary pyridinoline (39.0 1 19.8 nmol/mmol
of creat- inine to 55.7 1 25.5 nmol/mmol of creatinine) and deoxy- pyridinoline (8.4 1 7.1 nmol/mmol of creatinine to 14.9 1 9.4 nmol/mmol of creatinine). Percentage of body fat in the growth hormone group decreased (from 31 .9% 1 6.5% to 28.3% 1 7.0%), and lean body mass in— creased (from 59.0 1 8.5 kg to 61.5 1 6.9 kg). These changes were significantoompared with corresponding changes in the placebo group (P < 0.01 for all comparisons). Conclusions: Growth hormone administered to men with adult-onsetgrowth hormone deficiency at a dose adjusted according to semm IGF-1 levels increases bone density and stimulates bone turnover, decreases body fat and increases lean mass, and is associated with a low incidence of side effects.